希瑪醫療(03309.HK)預期2024財政年度收益約19.00億港元
格隆匯2月5日丨希瑪醫療(03309.HK)發佈公吿,根據目前可獲得的截至2024年12月31日止年度未經審核財務資料,撇除下述減值虧損的影響,集團預期公司權益持有人應占溢利將介於50百萬港元至60百萬港元(2023財政年度:62.0百萬港元),撇除下述減值虧損的影響,除利息、税項、折舊及攤銷前盈利(經調整EBITDA)將約為300百萬港元(2023財政年度:343.5百萬港元)。由於集團醫院及診所的商譽、物業、廠房及設備以及使用權資產預期錄得若干減值介於約195百萬港元至215百萬港元,集團預期錄得公司權益持有人應占虧損介於約130百萬港元至160百萬港元(2023財政年度:溢利62.0百萬港元)。以2024財政年度的收益而言,預期集團於2024財政年度的收益約19.00億港元,而2023財政年度的收益為19.24億港元。
減值虧損乃由於競爭激烈及2024年整體消費意欲減弱,導致若干醫院及診所的表現遜於預期。上述減值為一次性非現金開支,不會對集團的整體營運造成任何影響。
由於2024財政年度來自業務的整體現金流量強勁,董事會擬恢復2024財政年度的派息建議,但須待股東於2025年第二季舉行的應屆股東周年大會上批准後,方可作實。集團於2024財政年度來自業務的現金流量強勁,乃由於深圳希瑪愛康健口腔集團有限公司的牙科業務表現強勁、集團領先的香港眼科業務表現穩定,以及公司專注於大灣區眼科及牙科業務的策略所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.